Torrent Pharma Vista Division Product List

The steps taken by the government to reduce costs and bring down healthcare expenses drives the revenues of the pharma companies. Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers, which are on the rise.

Medicine spending in India is projected to grow 9-12% over the next five years, leading India to become one of the top 10 countries in terms of medicine spending.

IndiaвЂ™s domestic pharmaceutical market turnover reached Rs 1.4 lakh crore (US$ 20.03 billion) in 2019, up 9.8% from Rs 129,015 crore (US$ 18.12 billion) in 2018. India's biotechnology industry comprising biopharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics is expected grow at an average growth rate of around 30 per cent a y-o-y to reach US$ 100 billion by 2025. Pharmaceutical export include bulk drugs, intermediates, drug formulations, biologicals, Ayush and herbal products and surgical. Pharmaceuticals export from India stood at US$ 20.70 billion in FY20. The drugs and pharmaceuticals sector attracted cumulative FDI inflow worth US$ 16.50 billion between April 2000 and March 2020 according to the data released by Department for Promotion of Industry and Internal Trade (DPIIT).

The Union Cabinet has given its nod for the amendment of existing Foreign Direct Investment (FDI) policy in the pharmaceutical sector in order to allow FDI up to 100 per cent under the automatic route for manufacturing of medical devices subject to certain conditions. Indian pharmaceutical sector is expected to grow to US$ 100 billion, while medical device market is expected to grow US$ 25 billion by 2025. Indian pharmaceutical sector supplies ~50% of the global demand for various vaccines, 40% of generic demand in the US and 25% of all medicines in the UK. India is the largest provider of generic drugs globally. Pharma outsourcing into India and low cost Healthcare services are expected to be the key areas of growth in the near future.

The Nifty Pharma has delivered a CAGR of ~10% over the last decade. NSE Indices has developed Nifty Pharma Index to capture the performance of the companies in this sector. In addition, the inherent potential of biotechnology has also attracted many new companies and this is also a key growth area for Indian companies.

Indian companies have taken advantage of the opportunities in the regulated generics market in the western countries and made deep inroads especially in providing low cost equivalents of expensive drugs. Pharmaceuticals sector is one of the key sectors where Indian companies have created a global brand for themselves besides software.

Torrent Pharma Vista Division Product List